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ABSTRACT 
A vaccine against HIV is widely considered the most effective and sustainable way of preventing new infections. 
We previously conducted a phase I/II clinical trial using multi-clade, multigene HIV-DNA priming and boosting 
with the recombinant modified vaccinia Ankara (HIV-MVA) virus among healthy Tanzanian volunteers 
(HIVIS03 trial). The HIV-DNA vaccine contained seven plasmids expressing HIV-1 gp160 subtypes A, B, C, 
Rev B, Gag A, B and RTmut B and the recombinant HIV-MVA vaccine expressed CRF01_AE HIV-1 envelope 
(Env) subtype E and Gag-Pol subtype A. Sixty HIV-uninfected volunteers were randomized into three groups of 
20 to receive HIV-DNA or placebo intradermally (id) 1 mg or 3.8 mg intramuscularly (im) at 0, 1 and 3 months 
with a needle free device and were boosted with HIV-MVA 108-pfu or placebo im at 9 and 21 months. The 
vaccine regimen was safe and induced strong and potent immune responses. 
In this thesis we further explored the immune responses elicited by the HIV-DNA and HIV-MVA vaccine 
regimen and the effect of boosting with a third HIV-MVA or an envelope protein.  
In study I, we evaluated the HIV vaccine-induced antibody responses in sera collected from 29 HIVIS03 
vaccinees at baseline and four weeks after the second HIV-MVA. High titers of neutralizing antibodies (NAbs) 
(median 357) were detected using an infectious molecular clone (IMC)/peripheral blood mononuclear cell 
(PBMC) assay. The NAbs were significantly (but not completely) removed upon depletion of natural killer (NK) 
cells from PBMC (p=0.0039), indicating a role for Fc–receptor mediated antibody function. ADCC-mediating 
antibodies were demonstrated in the majority (97%) of the vaccinees against CRF01_AE and/or subtype B. The 
magnitude of ADCC-mediating antibodies against CM235 CRF01_AE IMC-infected cells correlated with NAbs 
against CM235 in the IMC/PBMC assay.  
In studies II and III we explored the duration of immune responses in individuals primed with HIV-DNA and 
boosted with HIV-MVA in the HIVIS03 trial and the effect of a late third HIV-MVA. Twenty volunteers who 
had previously received three HIV-DNA and two HIV-MVA immunizations in the HIVIS03 trial were given a 
third HIV-MVA, three years after the second HIV-MVA boost (HIVIS06). A high proportion of vaccinees 
showed durable binding antibodies, 90% to HIV-1 subtype C gp140 (median titer 200) and 85% to subtype B 
gp160 (median titer 100) three years after the second HIV-MVA. The majority of vaccinees had detectable 
ADCC–mediating antibodies, 70% against CRF01_AE virus–infected cells (median titer 239) and 84% against 
CRF01_AE gp120–coated cells (median titer 499). Furthermore, 74% of vaccinees still had IFN-γ ELISpot 
responses, 63% to Gag and 42% to Env. After the third HIV-MVA, there was an increase in Env-binding 
antibodies and ADCC-mediating antibodies relative to the response seen at the 3-years time point. The frequency 
of IFN-γ ELISpot responses increased to 95% against Gag or Env, and 90% to both Gag and Env, p = 0.064 and 
p = 0.002, respectively, after the third HIV-MVA. All 19 (100%) evaluable vaccinees had IgG antibodies to 
V1V2 CRF01_AE A244 after the second HIV-MVA with a median titer of 3200. A high proportion (75%) of 
the vaccinees still had V1V2 IgG antibodies to CRF01_AE A244 three years after the second HIV-MVA, which 
increased to 95% after the third HIV-MVA. The magnitude of response before and after the third MVA 
increased significantly from a median titer of 400 to 1600, p<0.0001, but not to the same level as after the second 
HIV-MVA (p=0.025). Surface plasmon resonance/Biacore analysis data supported the ELISA findings. V1V2-
specific IgG1 antibody responses were more frequently detected than V1V2-specific IgG3 antibodies. Anti-
V1V2 IgG1 responses decreased after three years but could be boosted by the third HIV-MVA in the majority of 
the vaccinees.  
In study IV, we evaluated the safety and impact of boosting with subtype C CN54rgp140 Env protein adjuvanted 
in glucopyranosyl lipid A-aqueous formulation (GLA-AF) in volunteers previously given three HIV-DNA, 
followed by two HIV-MVA in the TaMoVac 01 trial. Forty volunteers (35 vaccinees and five placebo recipients) 
were given two CN54rgp140/ GLA-AF immunizations 30–71 weeks after the second HIV-MVA. The vaccine 
was safe and well tolerated, except for one incident of asymptomatic hypoglycemia. After the second HIV-MVA 
vaccination, 34 (97%) of the vaccinees developed Env-specific binding antibodies, whereas 79% and 84% 
exhibited IFN-γ ELISpot responses to Gag and Env, respectively. Binding antibodies to subtype C, B and 
CRF01_AE Env were significantly boosted by the CN54rgp140/GLA-AF immunizations, while functional 
antibodies were not significantly boosted. In contrast, T-cell proliferative responses to subtype B MN antigen 
and IFN-γ ELISpot responses to Env peptides were significantly enhanced. 
In conclusion, the HIV-DNA prime/HIV-MVA boost regimen elicited potent antibody and cellular immune 
responses with remarkable durability, and a third HIV-MVA significantly boosted both antibody and cellular 
immune responses. Binding antibody responses and Env-specific cell-mediated immune responses but not 
functional antibody responses, increased after boosting with two CN54rgp140/GLA-AF immunizations 
following priming with HIV-DNA and HIV-MVA. 
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1 GENERAL BACKROUND 
1.1 Introduction 
The acquired immunodeficiency syndrome (AIDS) was first described in the early 1980s in 
homosexual men in USA [1,2]. The syndrome was defined by unusual diseases, including 
Pneumocystis carinii pneumonia and Kaposi’s sarcoma [1,2]. In 1983/1984, the human 
immunodeficiency virus (HIV) was identified as the cause of AIDS [3,4]. HIV is grouped 
into two types, HIV-1 and HIV-2 [5,6]. HIV-1 is the major cause of AIDS worldwide. AIDS 
occurs as results of progressive depletion of CD4+ T lymphocytes, which are the preferred 
target of the virus, leading to an immunodeficiency syndrome that paves the way to 
opportunistic infections and cancers [7,8]. Laboratory diagnosis of HIV infection is mainly 
based on the detection of HIV antibodies or the HIV antigen and viral nucleic acid. 
Prevention strategies include behaviour change, safe sex, use of condoms, HIV counselling 
and testing, screening of blood and blood products, harm reduction efforts for injecting drug 
users (IDUs), prevention of mother to child transmission by using antiretroviral drugs and 
male circumcision. The use of antiretroviral treatment (ART) to attack the virus and early 
treatment of the opportunistic infections help to minimize the risk of transmitting the virus as 
well as prolong life but does not cure the disease [9]. Development of a safe and effective 
HIV vaccine would certainly be the best way for the controlling the AIDS pandemic [10]. 
1.2 The epidemiology of HIV infection 
1.2.1 Global situation 
HIV continues to be a major global public health concern. In 2015, UNAIDS estimated that 
36.7 million (34.0 million–39.8 million) people were living with HIV including 1.8 million 
children (<15 years old). Since the beginning of the HIV epidemic, approximately 78 million 
people have become infected with HIV and 35 million people have died from AIDS-related 
diseases. The number of people worldwide who were newly infected with HIV in 2015 was 
2.1 million (1.8 million–2.4 million), a decrease from 3.1 million (3.0 million–3.3 million) in 
2000. Globally, new HIV infections have declined by 35% since 2000. In 2015, 1.1 million 
(0.94–1.3 million) people died from AIDS-related illnesses worldwide compared to 2 million 
(1.7–2.7 million) in 2005. Access to ART has led to the significant reduction of AIDS-related 
deaths [11].  
1.2.2 HIV infection in Sub-Saharan Africa 
The estimated number of people living with HIV in sub-Saharan Africa in 2015 was 25.6 
million (range 23.1–28.5 million). Women account for more than half the total number of 
people living with HIV in sub-Saharan Africa. Sub-Saharan Africa accounts for two-thirds of 
the global total of new HIV infections. Of the total number of HIV-infected individuals in 
Sub-Saharan Africa, 19 million (17.7–20.5 million), the vast majority live in East and 
Southern Africa. This accounts for 46% (960,000 ranging 0.83–1.1 million) of the global 
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total of new HIV infections in 2015. Between 2010 and 2015, new HIV infections declined 
by 14% in Eastern and Southern Africa where 470 000 people died of AIDS-related diseases 
in 2015. The number of AIDS-related deaths in Eastern and Southern Africa fell by 38% 
between 2010 and 2015 where 54% (10.3 million) people were accessing ART of all people 
living with HIV in the region [12].  
1.2.3 HIV and AIDS in Tanzania 
In 2015 an estimated 1.4 million Tanzanians were living with HIV, of whom nearly 28% 
were children (0-14 years) and 11.2% were young people aged 15-24 years. The overall 
estimated HIV prevalence is around 4.7% [13,14]. Heterosexual transmissions account for the 
vast majority (80%) of all HIV infections in Tanzania [15]. The HIV prevalence is higher 
among women of all age groups compared to their male counterparts (6.2 % among women 
and 3.8% among men) [16].These differences are more marked among young women and 
girls, indicating that women are more vulnerable to HIV infection in Tanzania. In 2015, 
54,000 people were newly infected with HIV and 36,000 people died from AIDS-related 
diseases. Access to ART has helped to minimize the impact of the HIV epidemic. As a 
consequence, between 2010 and 2015, the number of new infections decreased by more than 
20% and the number of people who died from AIDS-related illnesses halved [14].  
1.3 HIV virology  
1.3.1 Structure and replication of HIV 
HIV is a member of the Lentivirus genus of the Retroviridae family. HIV-1 was reported to 
originate from Simian immunodeficiency virus (SIV) cpz from chimpanzees (Pan 
troglodytes) [17,18] while HIV-2 originated from SIVsmm from sooty mangabeys 
(Cercocebus atys) and was transmitted to humans after cross-species infections on multiple 
occasions [18]. 
HIV viral particles are spherical with a diameter of 100-120 nm and are surrounded by a 
lipoprotein rich membrane. Each viral particle membrane includes glycoprotein heterodimer 
complexes comprised of trimers of the external surface gp120 and the transmembrane gp41 
[19,20]. The viral core contains two identical copies of single-stranded positive sense RNA 
molecules bound to a nucleocapsid (Figure 1). The retrovirus genome consists of the three 
major structural genes, gag, pol and env. Gag encodes the internal structural polyprotein of 
the virus and it is proteolytically processed into mature proteins; matrix, capsid and 
nucleocapsid. Pol encodes the enzymes reverse transcriptase (RT), integrase that mediates 
insertion of the provirus into the host genome and protease, which cleaves the precursor Gag 
polyprotein to produce structural proteins. Env encodes the surface glycoprotein and the 
transmembrane glycoprotein of the virion, which form a complex that interacts specifically 
with cellular receptor and co-receptor protein. The genome has six regulatory genes including 
vif, vpr, tat, rev, vpu and nef that encode proteins essential for the viral life cycle [19-21]. 
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Figure 1. Structure of HIV  
HIV infection commences with the attachment of the virion to the cell surface mediated by an 
interaction between the extracellular domain of HIV-1 gp120 and cellular receptors [19]. 
CD4 is the major receptor for HIV-1 and HIV-2 and the transmembrane chemokine receptors 
CCR5 and CXCR4 are the main HIV-1 co-receptors in vivo. The viral gp120 initially binds 
to the CD4+ T cells, which then triggers a conformational change in the host-cell envelope 
that allows binding of the co-receptor (either CCR5 or CXCR4), which is required for fusion 
between virus envelope and cell membrane [22]. After binding to the coreceptor, viral and 
cellular membranes fuse and the viral core is released into the cytoplasm of the cell. After 
uncoating, the viral RNA is reverse transcribed by the RT enzymes. Subsequently, double-
stranded proviral DNA migrates into the cell nucleus and is integrated into the cellular DNA 
by the integrase. The cellular RNA polymerase transcribes the proviral DNA. The mRNAs 
are translated by the cellular polysomes. Viral proteins and genomic RNA are transported to 
the cellular membrane and assemble into immature virions, which are released. Polypeptide 
precursors are processed by the viral protease to produce mature viral particles [19-22] 
(Figure 2). 
 4 
 
Figure 2. HIV replication cycle 
http://www.intechopen.com/source/html/16788/media/image3.jpeg 
1.3.2 HIV diversity and subtypes 
HIV-1 is classified into three major phylogenetic groups: group M (main), O (outlier), and N 
(non-M or non-O). Group M, which is responsible for the majority of HIV-1 epidemic 
infections worldwide is further subdivided into nine HIV-1 subtypes (A to D, F to H and J to 
K), which are approximately equidistant from one another [23-27]. The most prevalent HIV-1 
genetic forms are subtypes A, B, and C, with subtype C accounting for almost 50% of all 
HIV-1 infections globally. Subtype A viruses are prevalent in areas of central and eastern 
Africa (Tanzania, Kenya, Uganda and Rwanda) and in Eastern European countries. Subtype 
B is the main genetic form in western and central Europe, the Americas, Australia, Southeast 
Asia, northern Africa, and the Middle East. Subtype C is predominant in southern Africa and 
India, and subtype D in Central Africa [26-30]. The predominant HIV subtypes in Tanzania 
are A, C and D [31-33]. Up to 55 circulating recombinant forms (CRFs) have been reported 
around the world with CRF01_AE, CRF02_AG and CRF07_BC being the most common 
recombinant forms worldwide. Eight HIV-2 (A-H) groups have been identified, group A and 
B being the most common [7,34].  
1.4 HIV and AIDS 
1.4.1 Natural history of HIV infection 
The clinical course of HIV infection varies in patients from the time of acute primary 
infection to AIDS progression. Progression of HIV infection to AIDS leads to progressive 
reduction in the number of circulating CD4+ T cells, which over the duration of a number of 
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years results in immunologic decline and death due to opportunistic infections and neoplasms 
[35,36] (Figure 3). Progression time from initial HIV-1 infection to AIDS in industrialized 
countries is approximately 10-11 years in the absence of ART [37,38]. Studies conducted in 
Africa on the natural history of HIV infection show that the median survival from 
seroconversion to the development of AIDS is approximately 10 years [39-41]. Similar 
findings have been reported in the research conducted in developed Western countries 
[37,38]. However, the study populations differ in terms of age and gender, risk of death 
before the development of AIDS and access to chemoprophylaxis for opportunistic 
infections. The mode of transmission also differs among the cohorts, as does the definition of 
AIDS used by the contrasting studies.  
A study by Morgan et al in rural Uganda on individuals infected with HIV-1 showed that the 
median time from seroconversion to AIDS was 9.4 years and from AIDS to death was 9.2 
months. The mode of transmission of HIV infection was mainly heterosexual contact and the 
median age at seroconversion was 30 years [39]. It was documented in this study that the 
survival time varied with age at infection where the older patients tended to have shorter 
survival times compared to younger ones. The reported survival time of patients infected with 
HIV-1 in studies conducted in Africa is similar to the reported survival of infected patients in 
developed countries before the use of antiretroviral therapy [39,40]. 
In healthy HIV-uninfected individuals, the normal CD4+ T cell count is typically 600–1200 
cells/µl. HIV-infected individuals can carry the virus in their blood for several years before 
developing any serious symptoms. After a certain period of time the viral load increases in 
the blood, while the number of CD4+ T cells decline. Use of antiretroviral drugs help to slow 
down the viral replication and thus preserve CD4+ T cells and restore the immune system. 
In acute primary HIV infection, there are higher levels of the virus in the blood, which spread 
throughout the body, seeding in various organs, particularly the lymphoid organs. During this 
phase, HIV may integrate and hide in the host cell's genetic material. In the acute phase, there 
is a rapid decrease of the CD4+ T lymphocytes. Most HIV-infected people present with flu-
like or mononucleosis-like syndrome approximately 2–4 weeks following HIV infection. 
Lymphadenopathy occurs in approximately 70% of people with primary HIV infection. 
These symptoms usually subside within 2–3 weeks whereas generalized lymphadenopathy 
may persist [42]. During this period, the immune system tries to fight back with killer T cells 
(CD8+ T cells) and B-cells producing antibodies. Virus levels in the blood decrease 
significantly, while levels of CD4+ T cell tend to rebound as the patient enters the clinically 
latent stage of disease and for some individuals, the CD4+ T cell count may rise to the normal 
level. During clinical latency, HIV-infected individuals may remain free of HIV-related 
symptoms for several years though the virus continues to replicate in the lymphoid organs. 
The virus can also remain latent in the macrophages and resting T cells. 
The immune system ultimately deteriorates to the point that it is unable to combat other 
infections. The plasma viral load dramatically rises, while the number of CD4+ T cells 
decreases. At this stage, most patients present with symptoms such as severe weight loss and 
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fatigue. Without ART intervention, the condition progresses to full-blown AIDS, 
characterized by opportunistic infections, neurological damage, and cancers. Full-blown 
AIDS occurs when the CD4+ T cell counts are less than 200 cells/µl of blood. The common 
cause of morbidity and mortality in HIV-infected patients are mainly opportunistic 
pulmonary infections including tuberculosis, Pneumocystis jirovecii and pneumonia due to 
Streptococcus pneumoniae [43,44]. Other infections like oral candidiasis, cryptococcal 
meningitis, toxoplasmosis, gastroenteritis and severe viral infection including varicella zoster, 
cytomegalovirus and herpes simplex infections are also prevalent [43]. AIDS associated 
malignancies such as Kaposi’s sarcoma, Hodgkin’s disease, non-Hodgkin’s lymphoma and 
squamous cell carcinomas are frequently reported in chronically immunocompromised 
patients [45]. The majority of HIV-infected persons die with AIDS and most of them have 
very low CD4+ T cell counts at the time of death. Reports of studies conducted in Africa have 
shown that, HIV-1 subtype D is associated with more rapid disease progression, compared 
with subtype A, C and G [46-50]. However, a study conducted among Africans and Swedes 
found no differences in the rate of CD4+ T cell decline, clinical progression or plasma HIV-1 
RNA levels between HIV-infected patients with subtypes A, B, C or D over a mean 
observation period of 44 months [51].  
 
 
 
Figure 3: Clinical course of HIV-1 infection  
Source: http://upload.wikimedia.org/wikipedia/commons/a/a4/Hiv-timecourse.png 
1.4.2 Modes of HIV transmission 
The modes of transmission of HIV are different in different parts of the world and change 
over time within regions. Heterosexual intercourse is the main mode of HIV transmission in 
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many resource-poor countries including countries in sub-Saharan Africa [52]. Mother-to-
child transmission during pregnancy, at delivery or through breast-feeding, injecting drug use 
(IDU), sexual contact among men who have sex with men (MSM) and exposure to 
contaminated blood and blood products account for the remaining infections. In Latin 
America, most infections are acquired among MSM and through IDU, while heterosexual 
contact and injection of drugs are the most common modes of HIV transmission in Asia. A 
high virus load in blood during the acute HIV infection or in the asymptomatic period 
increases the risk of HIV transmission [53,54]. 
1.4.3 Immunopathogenesis of HIV infection 
The immunodeficiency induced by HIV infection is characterized by the depletion of cells of 
the immune system; CD4+ T lymphocytes, macrophages, monocytes and dendritic cells that 
express CD4. This effect is accompanied by activation of various components of the immune 
system, resulting in functional immunosuppression (i.e. reduced function of remaining CD4+ 
cells) and a form of inflammation that appears to underlie the increased risk of recurrent 
opportunistic complications occurring in patients with HIV infection. Insufficient immune 
response to HIV infection fails to control viral replication, provoking continued immune 
activation [20,55].  
During the natural course of the HIV-1 infections, the CD4+ T cell counts slowly drop, while 
plasma viremia rises in most patients. Following sexual transmission, HIV infects a mucosal 
surface and cells of the mucosa-associated lymphoid tissue. The virus binds to the CD4 and 
the CCR5 chemokine receptors, and infects dendritic cells (DC) and other cells of 
monocytes-macrophage lineage, as well as peripheral blood T cells. Infection of the CD4+ T 
cells, and cell activation by DC, contributes to the spread of HIV-1 within the lymphoid 
tissues. Reduction in the number of CD4+ T cells may occur as a consequence of direct HIV-
induced cytolysis, T cell-induced immune cytolysis and chronic activation as a result of the 
HIV antigen challenge leading to rapid terminal differentiation and death of T cells. HIV 
induces several cytopathic effects that may kill the infected T cells including an accumulation 
of non-integrated circular DNA copies of the genome, increased permeability of the plasma 
membrane, syncytia formation and apoptosis. Activated CD4+ T cells initiate immune 
response by the release of cytokines required for the activation of macrophages, other T and 
B cells and natural killer (NK) cells. When CD4+ T cells are unavailable or not functional 
antigen-specific cells are incapacitated and humoral responses are uncontrolled. The loss of 
CD4+ T cells leads to the occurrence of opportunistic intracellular infections that are the 
typical characteristics of AIDS [20,35,55,56]. 
1.4.4 Laboratory diagnosis of HIV infection 
HIV infection can be diagnosed by the detection of HIV-specific antibodies or antigen in 
serum or plasma or detection of viral nucleic acid using polymerase chain reaction (PCR) 
[57,58]. In Tanzania, the current national HIV testing algorithm includes the use of a simple 
rapid test (SD-Bioline HIV 1 / 2) for HIV screening followed by a second simple rapid test 
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(Uni-GoldTM HIV) if the first rapid test is positive. HIV enzyme-linked immunosorbent assay 
(ELISA) is used in case of discordant results between the two rapid tests. PCR is useful in 
testing infants of HIV-positive mothers because infants may carry maternal anti-HIV 
antibodies up to 18 months of age [58,59]. HIV RNA PCR is also used for monitoring viral 
load during ART and to confirm acute HIV infection in a situation where diagnosis has to be 
made before the usually time for seroconversion [60,61]. 
1.5 Innate immunity  
Innate immunity is the first line of defence against invading pathogens and plays a major role 
in restricting microbial infection including viruses. Innate immune cells recognize a 
conformational pattern of an organism rather than a specific epitope. The innate immune 
system recognizes incoming microbial pathogens through evolutionary conserved pathogen-
associated molecular patterns (PAMPs) and responds through intracellular signaling and 
subsequent cytokines production. The sensing of pathogens especially in viral infection is 
performed mainly by pattern recognition receptors  (PRRs) present either on the cell surface 
or within distinct intracellular compartments. The PRRs include Toll–like receptors (TLRs), 
the nucleotides–binding oligomerization domain protein like receptors (NLRs) and retinoic-
acid-inducible gene-I (RIG-I) [62,63]. RIG-1-like receptors are cytosolic sensors of viral 
RNA that respond to viral nucleic acids by inducing the production of the antiviral type 1 
interferon. The interaction between PRRs and PAMPs elicits the production of interferon 
(IFN), and pro-inflammatory cytokines and chemokines that recruit and activate cells of the 
innate immune system. These include macrophages, NK cells, neutrophils, DC, γδ T cells and 
NK-T cells, which are involved in the inhibition of viral replication in infected cells, as well 
as to activate adaptive immune response [64]. During HIV infection, the innate immune 
receptors such as TLR7 and TLR8 are usually activated causing the stimulation of effective 
DC and the production of IFNs and tumor necrosis factor α (TNF-α) that are involved in the 
inhibition of viral replication in infected cells [65-67].  
Mannose-binding lectins and complement are among the soluble components of the innate 
immunity, which express anti-HIV activity by directly causing viral lyses and also enhancing 
viral phagocytosis via macrophages. 
NK cells are an important component of the innate immune system that plays a role against 
HIV infection through its direct cytolytic effector functions against virally infected target 
cells and non-cytolytic antiviral effector functions. NK cells express soluble factors with 
antiviral function including IFN-γ, perforin, granzymes, FasL and TNF-α [68,69]. In addition 
NK cells trigger secretion of β-chemokines including MIP1α, MIP1β, and RANTES, which 
suppress CCR5-tropic HIV infection by binding to and down-modulating the CCR5 co-
receptors [70,71]. 
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1.6 Adaptive immunity 
The adaptive immunity system is composed of highly specialized cells that eliminate 
pathogens. It is specific to a particular pathogen and can also provide long-lasting protection. 
Adaptive immunity generates immunological memory after an initial encounter with a 
pathogen and leads to an enhanced response to subsequent encounters with that pathogen. 
The system includes both humoral immunity and cell-mediated immunity components [72].  
Humoral immunity consists of B cells, antibodies, and type 2 helper T cells (Th2). Type 2 
helper T cells are included in the humoral immune system because they present antigens to 
immature B cells, which undergo proliferation to become specific to the presented antigen. B 
cells are produced and mature in bone marrow tissues, and contain B cell receptors that bind 
to antigens. B cells produce antibodies that circulate through the plasma. Antibodies bind to 
pathogens to opsonize them, making it easier for phagocytic cells to bind to and destroy the 
pathogen. Antibodies neutralize the toxins produced by certain pathogens and provide 
complement pathway activation, in which circulating proteins are combined in a complex 
cascade that forms a membrane attack complex on a pathogen cell membrane, which lyses 
the cell. 
Cell-mediated immunity consists of T cells that express either CD4+ or CD8+ depending on 
signals that occur during T cell maturation. Cell-mediated immunity is controlled by type 1 
helper T cells (Th1) and cytotoxic T cells. These cells are activated by antigen presenting 
cells (APC) causing them to mature rapidly into forms specific to the antigen. Helper T cells 
(Th1) facilitate the organization of immune response by guiding cytotoxic T cells to destroy 
virus-infected cells. They produce cytokines that guide cytotoxic T cells to pathogens and 
activate macrophages.  
Cytotoxic T cells bind to the major histocompatibility complex (MHC) class I molecules. 
They destroy the pathogen/virus by releasing granules that contain the cytotoxic perforin and 
granzyme, which lyse small pores in the membrane of the virus. Helper T cells secrete 
cytokines such as interferon-gamma, which can activate cytotoxic T cells and macrophages. 
Memory T cells are created after an adaptive immune response subsides, retaining the 
presented antigen. They rapidly proliferate and differentiate into helper and cytotoxic T cells 
that are specific to that antigen should it be detected in the body again [72,73]. 
1.7 Immune responses to HIV infection 
1.7.1 HIV-specific humoral immune response   
The first free antibody response to HIV-1 infection is anti-gp41, which appears 
approximately two weeks after detectable viremia, while anti-gp120 antibodies appear four 
weeks after detectable plasma viral RNA [74]. These antibodies lack neutralizing capacity 
and do not appear to have a significant impact on initial control of viremia [75,76]. 
Antibodies with neutralizing capacity develop later than other immune responses 
approximately 12 weeks after initial infection and are principally targeted at the envelope 
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glycoprotein complex, gp41 and gp120 subunits, which mediate viral entry into a CD4+ T 
cell. Neutralizing antibodies (NAbs) bind the cell-free virus and prevent infection of host 
target cells, thus inhibiting viral replication [77,78]. However, because of extensive 
variability in the envelope gene, mutant viruses rapidly emerge, which are not neutralized by 
the antibodies that were elicited by the original strain. Broadly NAbs are not routinely made 
in HIV-1 infection. Studies have shown that during the course of natural infection, both type-
specific and broadly cross-reactive NAbs are elicited [79-82]. However, only 15% to 25% of 
HIV-1-infected individuals will develop broadly NAbs that can mediate neutralization of 
diverse viral isolates [83-86].  
HIV-specific antibodies can eliminate HIV-infected cells via antibody-dependent cellular 
cytotoxicity (ADCC) in the presence of effector cells. This functional role of antibodies 
depends on the interaction of Fc-receptors on the surface of effector cells [76,87]. Potential 
effector cells include NK cells, macrophages, DC, γδT-cells, and neutrophils. ADCC occurs 
when HIV-1-specific antibodies, bind to their antigens presented on the surface of infected 
cells. Fc-receptors on NK cells recognize the Fc part of the antibodies. Cytotoxic activities 
are then induced by the NK cells killing the virus-infected cell [87,88]. 
1.7.2 HIV- specific cellular immune response 
T lymphocytes play an important role in the control of HIV infection. Lack of CD4+ T cells 
during HIV infection tends to affect CD8+ T cell priming, thus reducing viral clearance. After 
primary infection with HIV, the rapid appearance of cytolytic T cell responses, mainly CD8+ 
T cell responses, is associated temporally with a decline in plasma viral load. CD8+ T cells 
help to control HIV replication by triggering a cytolytic response. The CD8+ T cells release 
perforin and granzymes, which destroy the HIV-infected cells before they produce virions 
[73,89,90]. CD8+ T cells can also mediate cytolytic activity against viral targets via 
expression of Fas ligand by binding to the CD95 on the surface of target cells, which induces 
apoptotic cell death. CD8+ T cells also secrete soluble factors with antiviral activity including 
cytokines (INF-γ, TNF-α, IL-2) and beta chemokines (MIP-1α and MIP-1β), which bind to 
CCR5 decreasing the ability of HIV entry into the susceptible cells [91]. An inverse 
correlation between plasma HIV level and HIV-specific T cell responses has been reported in 
untreated HIV-infected individuals. Furthermore, long-term non-progressive infection has 
been associated with both strong HIV-specific cytotoxic T lymphocyte activities and with 
robust Gag specific CD4+ T cell proliferative responses [92,93]. 
The potential role of cytolytic CD4+ T cells in the control of HIV infection has been reported. 
The cytolytic CD4+ T cells express cytolytic markers similar to cytolytic CD8+ T cells and are 
distinct from Th1 CD4+ T cells. Moreover, HIV-specific cytolytic CD4+ T cells expressing 
the degranulatory marker (CD107a) have been demonstrated in HIV-infected patients who 
controlled HIV replication for prolong period of time [94,95].
  11 
1.8 HIV prevention and vaccine 
1.8.1 Prevention of HIV infection 
Several behavioural and biomedical strategies can reduce HIV-1 infection, and health 
education plays an important role in tackling the spread of HIV. This includes the provision 
of education to control transmission, such as the practice of safe sex, monogamous 
relationships and use of condoms to reduce the risk of exposure to HIV, as well as avoiding 
needle sharing in intravenous drug abusers and the reuse of needles in clinics. Blood and 
blood products, tissues and organs must be screened for HIV infection before donation. Other 
prevention measures include counseling campaigns, screening and treatment of sexually 
transmitted diseases, male circumcision and the use of ART to prevent mother-to-child 
transmission [96-98]. Pre-exposure antiretroviral prophylaxis and post-exposure with 
tenofovir-based regimens has been suggested for HIV prevention in high-risk populations 
[99,100]. 
1.8.2 HIV vaccine strategies  
Several HIV vaccination strategies have been tested in phase I/II trials [101-106]. Live 
attenuated vaccines are the most potent vaccines against viral infections. The ability of an 
attenuated viral vaccine to elicit protective immune responses mostly depends on the ability 
of the virus to replicate in the host. Vaccination with SIV live attenuated vaccines has been 
used in SIV/ macaque-models resulting in potent immune response that conferred protection 
[107-110]. However, the use of live attenuated HIV-1 has not been attempted in humans 
because of safety concerns.  
Conventionally, the same vaccines can be administered multiple times as homologous boosts. 
Vaccines that apply the homologous prime–boost approach include recombinant protein 
subunit vaccines, (e.g hepatitis B vaccine), polysaccharide vaccines (e.g Haemophilus 
influenzae type b vaccine) and inactivated vaccines (e.g. hepatitis A vaccine). In the search 
for effective vaccines against HIV infection, new approaches including heterologous prime–
boost immunizations have been designed and reported to be more immunogenic than the 
homologous prime–boost concepts [111,112]. A similar vaccine approach has also been 
suggested for other diseases such as hepatitis C virus, tuberculosis and malaria. Heterologous 
prime-boost regimens using DNA and viral vectors or recombinant proteins have been shown 
to induce broad and potent cellular and humoral responses and to reduce the attenuation 
effects of viral vector specific immunity [101-104,113].  
DNA vaccines have been reported to prime cellular and humoral immune responses, when 
boosted with recombinant vectors [102-106]. The most common vectors used include 
modified vaccinia virus Ankara (MVA), fowlpox and adenoviral vectors [114-116]. Various 
combinations of prime-boosts have been tested in humans including recombinant DNA and 
the poxvirus vector NYVAC or MVA, adenovirus vectors alone or in combination with 
plasmid DNA-based vaccines, and were shown to induce strong cellular immune responses 
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[104,117,118]. In the RV144 efficacy trial, immunizations with canarypox (ALVAC–HIV 
vCP1521) and HIV envelope protein (AIDSVAX B/E gp120) generated protective immune 
responses among Thai heterosexual individuals [119].  
The use of adjuvants such as IL-12, 1L-15, glucopyranosyl lipid A (GLA-AF) and 
granulocyte macrophage colony-stimulating factor has also been explored to enhance 
vaccine-induced immune responses [120-122]. 
Various modes of vaccine delivery have been employed such as either sequential or parallel 
administration, administration using needle free devices (Bioject or Zetajet), electroporation 
and/or administration by using a syringe. Vaccines can also be given id, im, intranasally or by 
the oral route. 
1.8.3 Possible correlates of protection against HIV infection 
The role of antibodies in preventing HIV-1 acquisition has been suggested by passive and 
active immunization studies in nonhuman primates [123-125]. Previous studies have shown 
that passively administered NAbs protect against pathogenic chimeric simian/human 
immunodeficiency virus (SHIV) challenge in rhesus macaque models [123,124]. In addition, 
HIV-specific monoclonal antibodies infused intravenously to macaques have been shown to 
protect against intravenous and mucosal chimeric SHIV challenge [126,127]. A study by 
Haigwood et al found that passively transferred antibodies from HIV-1 infected individuals 
protected the chimpanzees from HIV-1 infection and rhesus macaques from SIV infection. In 
addition, early intervention using passive immunoglobulin was reported to control the viral 
replication and maintain a very low viral load and delay disease progression in SIV infection 
of macaques [128,129]. 
Cellular immunity plays a potential role in the control of HIV infection. In a situation where 
HIV infection occurs after exposure, cellular immune responses will be needed to control 
virus replication and prevent the development of disease. In HIV and SIV infection a 
profound expansion of virus specific CD8+ T cells occurs during acute infection coincident 
with control of viremia, suggesting a crucial role for CD8+ T cells in containing viral 
replication [130,131]. Cytotoxicity, cytokines and phenotypic markers have been reported as 
potential correlates of CD8+ T cell immunity. The presence of strong CD4+ and CD8+ HIV-1-
specific T cell responses in HIV-1-infected individuals that are long-term non-progressors has 
been reported [132,133].  
The importance of CD8+ T lymphocytes in the control of virus replication has been reported 
in acute and chronic SIVmac infection of rhesus monkeys [134]. Schmitz et al showed that 
depletion of CD8+ T lymphocytes from rhesus monkeys during chronic SIV infection led to 
marked increase in viremia [130]. In the study where rhesus macaques were challenged with 
a chimeric SHIV after CD8+ T cell depletion, a higher viral load and profound CD4+ T cells 
depletion were detected in the CD8+ T cell depleted macaques as compared to monkeys with 
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intact CD8+ T cells, further highlighting the importance of CD8+ T cells in the control of SIV 
replication [135].  
Virus-specific CD8+ cytotoxic T lymphocyte activity plays an important role in the control of 
viral replication and subsequently HIV-1 viremia during primary infection, as well as 
reduction in HIV-1 disease progression [136,137]. HIV-1 specific cytotoxic T lymphocyte 
responses have been demonstrated in HIV-exposed, persistently seronegative individuals in 
multiple cohorts [138-141]. Resistance to HIV-1 infection among sex workers who remained 
HIV-uninfected for many years despite high-risk sexual activity has also been reported in 
Nairobi, Kenya and elsewhere [142-144]. Goh et al found that the protection against HIV-1 
infection in persons with repeated HIV exposure was attributed to T cell immunity rather than 
inherited CCR5 HIV-1 co-receptor defects [145]. 
Innate immune responses, such as increased NK cell activity, have been shown to correlate 
with protection from infection in high-risk cohorts of HIV-exposed but uninfected 
individuals, including HIV-exposed infants born to HIV-infected mothers, IDUs and HIV-1 
discordant couples [146,147]. Increased NK cell degranulation (CD107a) and NK cell 
activation marker (CD69) expression is also associated with resistance to infection in highly 
exposed, uninfected individuals [147,148]. Over-expression of inherited protective NK 
KIR3DL1 and KIR3DS1 receptor alleles in highly exposed seronegative partners of HIV-1-
infected subjects has been reported [149]. 
Mucosal immune responses particularly HIV-1 specific IgA, but not IgG have been 
demonstrated at mucosal sites as well as in genital tract secretions in exposed HIV-uninfected 
sex workers and heterosexual partners of HIV-1 infected subjects but not in HIV-1 infected 
sex workers, suggesting that mucosal antibodies, in the absence of systemic IgG responses, 
correlate with protection against HIV-1 infection [150]. 
Higher titers of HIV-1 gpl20-specific ADCC–mediating antibodies were reported to correlate 
inversely with the rate of disease progression. Rapid progressors had significantly lower titers 
of ADCC-mediating antibodies against HIV-1 gp120 than non-rapid progressors [151]. 
Likewise, in a cohort of long-term slow-progressors, high ADCC responses were 
significantly more common than in rapid progressors [152]. Higher levels of ADCC-
mediating antibodies were also reported in HIV-1 elite controllers who had undetectable 
viremia compared to viremic individuals [153,154]. Results from an experimental study, 
showed that potent ADCC activity developed in rhesus macaques immunized with live-
attenuated SIV and was associated with complete protection after pathogenic SIV challenge 
[107]. Furthermore, studies have shown that the magnitude of ADCC antibody responses 
correlates inversely with the viral load in acute SIV infection in macaques [155]. In addition, 
ADCC-mediating antibodies have been shown to protect against HIV-1 infection in mother-
to-child transmission [156].  
Antigen–specific IgG3 antibodies have been shown to correlate with long-term control of 
Plasmodium falciparum in malaria cases [157]. Early appearance of IgG3 specific NAbs in 
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individuals infected with Chikungunya virus was associated with clearance of the virus and 
long-term clinical protection [158]. IgG3 has a greater content of neutralizing paratopes 
compared to other IgG subclasses [159]. Notably IgGl and IgG3 are known to interact with 
Fc-mediating receptor functions, including ADCC effector cells, which triggers killing of 
HIV-infected cells [160]. IgG2 and IgG4 have weak affinities for Fc-receptor function and 
have been linked with a lack of protection to diseases. Reports suggest that IgG4 responses 
are associated with progression to AIDS [160].  
1.8.4 Lessons learnt from HIV vaccine efficacy trials: Phase IIb and III  
Clues to immune correlates of protection from infection have recently been derived from 
clinical HIV vaccine phase IIb and III trials. 
To date, six HIV vaccine efficacy trials have been conducted worldwide. The VAX004 trial 
using AIDSVAX® B/B vaccine was conducted among MSM and women at high risk of 
HIV-1 transmission in the USA and Europe with the aim of inducing humoral immune 
responses [161]. The AIDSVAX® B/B is a bivalent vaccine containing the monomeric 
rgp120 HIV-1 envelope antigen from the subtype B MN isolate and gp120 GNE8 in alum. 
High titers of NAbs elicited against HIV-1 MN tier 1 correlated inversely with risk of HIV 
infection, but the vaccine did not show protection against HIV-1 acquisition [162]. 
AIDSVAX® B/E was tested among IDUs in the VAX003 trial conducted in Thailand [163]. 
The AIDSVAX® B/E vaccine contained rgp120 proteins from subtype B MN strain and 
CRF01_AE CM244. The VAX003 vaccine regimen generated high levels of NAbs capable 
of neutralizing tier 1, but not tier 2 viruses. The vaccine regimen also elicited IgG1 
antibodies, very little IgG3 and higher levels of IgG4 [164]. The VAX003 trial did not 
prevent HIV-1 infection or delay disease progression in IDUs. The Step (HVTN 502) and 
Phambili (HVTN 503) vaccine trials were designed to test whether the vaccine inducing cell-
mediated immune response could prevent HIV infection or reduce plasma viremia following 
HIV infection. In the Step (HVTN 502) trial, the MRKAd5 gag/pol/nef subtype B vaccine 
was tested among MSM and high-risk women in North and South America, the Caribbean, 
and Australia. The vaccine induced IFN-γ ELISpot responses in a majority of vaccine 
recipients, but did not confer protection against HIV acquisition or reduce the plasma viral 
load after acquisition [165,166]. The same vaccine regimen was also evaluated in the HVTN 
503/Phambili study that enrolled heterosexual men and women in South Africa [167]. 
Similarly, no vaccine efficacy was demonstrated among the vaccine recipients. There was no 
significant decrease in the HIV-1 plasma viral load in the vaccine recipients compared with 
the placebo recipients in both the Step and Phambili trials [165-167]. Another vaccine 
consisting of gag/pol/env subtype A/B/C DNA prime with a matched recombinant Ad5 boost 
was tested in the HVTN 505 trial among MSM in North America [168]. This vaccine 
regimen was designed to induce both functional antibodies and cell-mediated immune 
responses. The vaccine induced polyfunctional CD4+ and CD8+ T cells, NAb against easy to 
neutralize viruses and binding antibodies to multiple subtypes [168,169]. The trial was 
stopped due to futility and there was no efficacy against HIV-1 acquisition. A study 
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conducted in non-human primates, using the same vaccine regimen showed a trend of 
protection against intra-rectal challenge with heterologous SIVsmE660, but not against 
SIVmac251 infection [170], indicating that the vaccine can protect against a certain virus 
strain. The RV144 trial, evaluated the protective effect of a prime-boost regimen, consisting 
of a canarypox-vectored vaccine (ALVAC-HIV vCP1521) and an HIV envelope protein 
(AIDSVAX® B/E) among HIV-uninfected heterosexual men and women, who were at low 
risk of acquiring HIV infection in Thailand. The trial showed a modest efficacy of 31.2% at 
42 months [119]. This trial gave an insight into the immune correlates of infection risk, which 
is an important step in the development of an HIV vaccine. The regimen induced binding 
antibodies against HIV-1 Env, CD4+ T cell proliferative responses, CD8+ T cell responses 
and NAb against T cell line-adapted viruses of subtype B and CRF01_AE. In the analysis of 
immune correlates of risk of HIV infection in the RV144 trial, it was found that antibodies 
against the V1V2 region of HIV-1 Env inversely correlated with the risk of HIV infection, 
while the presence of IgA Env-binding antibodies was associated with a lack of protection 
[171]. Moreover, ADCC-mediating antibodies and antibodies to the V3 region correlated 
with reduced risk of HIV infection in vaccinees with low IgA Env binding antibody titers 
[171,172]. The IgG1 and IgG3 antibodies targeting the crown of the V2 region of HIV Env 
were more frequently induced in the RV144 Thai trial compared to the non-protective 
VAX003 trial [164]. Furthermore, the frequency and magnitude of anti-V1V2 IgG3 
responses correlated with decreased risk of HIV-1 infection in the RV144 trial [173]. There 
was no effect on levels of viral load or CD4+ T cell count post infection. Notably the 
vaccination did not affect the clinical course of HIV-1 disease after infection. 
1.8.5 Challenges in developing an HIV vaccine 
Vaccines are historically the core health intervention for prevention of infectious diseases and 
would provide the most cost-effective way to reduce HIV-1 infection. However, the 
development of an effective vaccine against HIV-1 has faced multiple scientific, logistic, 
economic and social challenges. The ability of HIV to evade host immunity and frequently 
mutate makes development of an effective vaccine enormously challenging. The 
extraordinary sequence diversity of HIV-1 makes it difficult to obtain the appropriate 
immunogens for a vaccine [174,175]. Natural infection does not generate protective immune 
responses capable to eradicate the virus or prevent progression to disease. The HIV-1 
envelope glycoprotein is comprised of variable regions that elicit type-specific NAb with 
limited breadth, whereas the conserved regions like the CD4 binding site are hidden and 
poorly exposed to the immune system. Broadly NAbs develop in 20% of people within two 
to three years after HIV infection, but the ability of these antibodies to prevent disease 
progression is limited [84]. Lack of clear immune correlates of protection in humans is 
another key challenge, since HIV-1-infected patients are unable to clear the virus. The study 
assessing the immune-correlates of protection in RV144 generated the hypotheses that V1V2-
specific antibodies may have contributed to the protection seen, while high levels of Env-
specific IgA antibodies may have weakened the effects of the protective antibodies. There is a 
possibility that vaccines that are designed to induce higher levels of V1V2 antibodies and 
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lower levels of Env-specific IgA antibodies may improve the efficacy against HIV-1 
infection [171]. Thus the limited although increasing knowledge of immune-correlates of 
protection in humans call for more research in this area. Lack of predictive animal models 
limit researchers to study the vaccine’s efficacy under various viral challenges, as well as to 
investigate chemotherapeutic drugs. Chimpanzees have been successfully infected with the 
virus, and shown to generate immune responses, but they show varied clinical course of 
infection to humans. SIV and chimeric SHIV infection in rhesus macaques are useful animal 
models for HIV vaccine studies but so far no appropriate animal models have allowed 
replication of HIV and disease development similar to that found in humans [176,177]. HIV 
attacks cells of the immune system preferentially CD4+ T cells, a specific subset of immune 
cells that help orchestrate all of the other types of immune responses against pathogens. HIV-
1 integrates as a provirus into the chromosomes of long-lived reservoir memory T-cells 
where it can persist in a latent state narrowing the opportunity for the immune system to clear 
infection. Infection and destruction of CD4+ T helper cells weakens the effectiveness of 
immune responses. There is also a limited interest of the pharmaceutical industry and limited 
long-term sustained commitment from governments and donors [178].  
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2 RATIONALE OF THE STUDY 
Several preventive interventions have been described, including pre-exposure prophylaxis 
and the use of ART, as prevention for HIV infection but definite control of the HIV epidemic 
will be achieved mainly with the development of a safe and effective vaccine. Therefore, 
there is still a need to continue searching for an efficacious vaccine against HIV infection. 
Several studies using various HIV vaccine strategies have been conducted so far. 
Heterologous prime boost regimens using DNA, viral vectors, and/or recombinant proteins 
have been shown to generate HIV-specific cellular and humoral immune responses 
[101,179,180]. In the RV144 trial that used prime boost strategies, a moderate efficacy of 
31.2 % was attained. In the Thai RV144 trial, ADCC–mediating antibodies and antibodies to 
the V1V2 region of HIV-1 Env correlated with reduced risk of HIV infection in vaccinees 
with low level of IgA Env binding antibodies. However, the immune responses elicited in the 
RV144 trial waned quickly [171].  
We conducted a phase I/II HIV vaccine trial in Tanzania using priming with multigene, 
multiclade HIV-DNA and boosting with HIV-MVA among healthy individuals. The vaccines 
were safe and highly immunogenic. Cellular and humoral immune responses particularly 
binding antibodies and NAb responses using an IMC/PBMC assay were demonstrated in the 
majority of vaccinees after three HIV-DNA and two HIV-MVA vaccinations. Study I was 
conducted to determine the role of NK cells in the NAbs detected following the discrepancy 
shown between IMC/PBMC assay and TZM-bl pseudovirus assay, and explored whether 
ADCC–mediating antibodies were also elicited by HIV-DNA/MVA vaccine regimen. There 
is limited data on the longevity of immune responses induced following HIV immunization. 
Notably, few studies have assessed the duration of immune responses in HIV vaccine trials, 
as well as whether a late boost has an added value on boosting and maintenance of immune 
responses, which is needed for long-term protection. Thus, study II and III were conducted to 
explore the duration of immune responses in a subset of HIVIS03 vaccinees given three HIV-
DNA and two HIV-MVA vaccinations. The effect of a late third HIV-MVA was also 
evaluated in these studies. 
DNA vaccines have been shown to prime cellular and humoral immune responses after 
boosting with recombinant vectors [181]. We have previously reported that intradermal 
priming with HIV-DNA, followed by boosting with HIV-MVA generated broad and potent 
immune responses [102]. In the TaMoVac 01 trial, volunteers were primed three times with a 
standard regimen of five injections of HIV-DNA 1000 µg dose (three Env and two Gag 
encoding plasmids) versus a simplified regimen of two injections of HIV-DNA 600 µg dose 
Env and Gag encoding plasmid pools, each delivered separately or combined, and boosted 
twice with HIV-MVA. The vaccine was safe and cellular immune responses were efficiently 
primed by the DNA immunizations, irrespective of modality of administration and dose 
[182]. Study IV was conducted to determine the safety and immunogenicity of adding two 
adjuvanted Env proteins in volunteers previously given three HIV-DNA/placebo and two 
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HIV-MVA/placebo vaccinations in the TaMoVac 01 trial. This was the first HIV clinical 
vaccine trial to combine HIV-DNA, HIV-MVA and adjuvanted Env protein vaccinations. 
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3 OBJECTIVES  
3.1 BROAD OBJECTIVE 
To monitor and characterize humoral and cellular immune responses, induced by an HIV 
vaccine regimen that combines a plasmid-DNA priming vaccine with a MVA boosting 
vaccine with or without rgp140 immunization. 
3.2 SPECIFIC OBJECTIVES 
Paper I:  To determine the role of NK cells in the neutralizing activity observed in 
 PBMC assays, using sera from the HIVIS03 vaccinated volunteers, and to 
 explore potential Fc –receptor mediated ADCC antibody responses.  
Paper II:  To assess the duration of immune responses and the effect of a late third 
 HIV-MVA boost in HIVIS03 volunteers previously given three HIV-DNA 
 and two HIV-MVA immunizations in Dar es Salaam, Tanzania (HIVIS06).  
Paper III: To determine the VIV2 antibody responses induced by HIV-1 DNA priming 
 followed by HIV-MVA boosting in healthy Tanzanian Volunteers 
 (HIVIS03/06). 
 Paper IV: To assess safety and the impact of boosting with subtype C rgp140 envelope 
 protein adjuvanted in glucopyranosyl lipid A-aqueous formulation (GLA-AF) 
 in Tanzanian  volunteers previously given three HIV-DNA and two HIV-MVA 
 immunizations (TaMoVac 01/rg140). 
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4 METHODS 
4.1 Study design and population 
HIV vaccine-induced immune responses were evaluated in serum or plasma samples, 
collected from healthy Tanzanian volunteers participating in a phase I/II placebo-controlled 
double blind trial using multi-clade, multigene HIV-DNA priming and HIV-MVA boosting 
(HIVIS03/06 trial) (Paper I, II, III). In the HIVIS03 trial, 60 HIV-uninfected volunteers were 
randomized into three groups of 20 volunteers and received placebo or 1 mg HIV-DNA 
intradermally (id) or 3.8 mg intramuscularly (im). The DNA plasmids expressing HIV-1 
gp160 subtypes A, B, C; Rev B; Gag A, B and RTmut B were given at months 0, 1 and 3 
using a needle-free Biojector device. Recombinant MVA expressing CRF01_AE HIV-1 Env 
subtype E and Gag-Pol subtype A was delivered im by needle at months 9 and 21. Twenty 
volunteers, who had previously received three HIV-DNA and two HIV-MVA immunizations 
in the HIVIS03 trial, were recruited in the HIVIS06 trial and given an additional late third 
HIV-MVA immunization three years after the second HIV-MVA boost, and followed up for 
one month (Paper II and III). The vaccination schedule and immunogenicity time points are 
summarized in Table 1 and Figure 4. 
Study IV was built upon the TaMoVac 01 trial, a previous phase IIa randomized placebo 
double blind clinical trial, conducted in Tanzania [182]. The trial included 120 healthy HIV-
uninfected volunteers from two centers, the Muhimbili University of Health and Allied 
Sciences (MUHAS) in Dar es Salaam, and the National Institute for Medical Research 
(NIMR)-Mbeya Medical Research Center (NIMR-MMRC) in Mbeya. Participants in the 
TaMoVac 01 study received HIV-DNA containing seven plasmids expressing HIV-1 gp160 
subtypes A, B, and C at weeks 0, 4 and 12 id, using the Zetajet device and were boosted im 
with HIV-MVA expressing CRF01_AE at weeks 30 and 46. The plasmids were delivered in 
combined or separated pools (Pool 1: EnvABC/RevB, Pool 2: GagAB/ RTmutB). In an 
amendment to the protocol, 40 volunteers (35 vaccinees and five placebo recipients) who 
received three HIV-DNA/placebo and two HIV-MVA/placebo immunizations were given 
two CN54rgp140/GLA-AF immunizations im 30-71 weeks after the second HIV-MVA 
vaccination four weeks apart (TaMoVac/rgp140 trial) (paper IV). Randomization, doses and 
routes of immunization are summarized in table 2. 
4.2 Vaccines and adjuvant 
The HIV-1 DNA vaccine was developed by the Wahren research group at the department of 
virology, Swedish Institute for Infectious Disease Control/Karolinska Institute, Sweden and 
manufactured by Vecura, (Huddinge, Stockholm, Sweden). The HIV-DNA vaccine was 
comprised of seven plasmids expressing HIV-1 gp160 subtypes A, B, C; Rev B; Gag A, B 
and RTmut B (Figure 4) [183,184]. The HIV-MVA vaccine is a recombinant live non-
replicating poxvirus vector that was genetically engineered to express HIV-1 gp150 (subtype 
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E, isolate CM235) and Gag and Pol (integrase-deleted and reverse transcriptase non-
functional, subtype A, isolate CM240.) The HIV-MVA was developed by P. Earl and B. 
Moss from The Laboratory of Viral Diseases, NIAID, NIH USA and manufactured by The 
Walter Reed Army Institute for Research (WRAIR) Pilot Bio production facility (Forest 
Glen, MD, USA) [185].  
CN54rgp140 is a recombinant subtype C Env protein derived from a Chinese viral isolate 
97CM001, clone p97CN54 [186,187]. CN54rgp140 was manufactured according to GMP 
specifications by Polymun Scientific, Vienna, Austria (accession number AF286226). 
GLA-AF is an aqueous formulation containing glucopyranosyl lipid A, a completely 
synthetic monophosphoryl lipid A (MPL)-like molecule [188]. GLA-AF was manufactured 
to GMP specifications by The Infectious Disease Research Institute (IDRI) Seattle, USA. 
 
 
Figure 4. Vaccines, immunization schedule and immunogenicity follow-up time points 
(Study 1-III) 
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Table 1. Vaccination schedule for HIVIS03 and HIVIS06 trials 
HIVIS03 trial   HIVIS06 trial 
Vaccine N HIV-DNA 
immunization 
HIV-MVA 
immunization 
N HIV-MVA 
immunization  
Time point    Months 0, 1 and 3 Months 9 and 21   Month 53-59 
Group I 20 3.8 mg id  108 pfu im 11 108 pfu im 
Group II 20 1 mg id 108 pfu im 9 108 pfu im 
Group IIIa 10 Saline im Saline im     
Group IIIb 10 Saline im  Saline im    
 
Table 2. Randomization, doses and routes of immunization (Study IV) 
TaMoVc 01 regimen  Amendment 
Vaccine N HIV-DNA ID HIV-MVA IM N Protein IM 
Time 
point  
  Weeks 0, 4 and 12 Weeks 30 and 
46 
  Two immunizations with 4 weeks 
interval after week 58  
Group I 36 600 µg (combined pools)  108 pfu  10 100 µg CN54gp140 5 µg GLA-AF  
Group II 36 600 µg (separate pools)  108 pfu 11 100 µg CN54gp140 5 µg GLA-AF 
Group 
III 
36 1000 µg (separate pools)  108 pfu 14 100 µg CN54gp140 5 µg GLA-AF 
Group 
IV 
12 Saline ID 2 or 5 x 0.1 ml  Saline IM 5 100 µg CN54gp140 5 µg GLA-AF 
N: number of participants. Combined pools refer to a combination of pool 1 (EnvABC/RevB) and pool 2 
(GagAB/RTmutB) and separated pools refer to separate administration of pool 1 and 2 into the left and right 
arm, respectively 
4.3 Safety assessment 
Safety was assessed by solicited local and systemic events, recorded in diary cards following 
each immunization. Safety assessments were performed at each visit. Information on adverse 
events recognized to be associated with licensed vaccines was collected on diary cards by 
participants, for one-week following each vaccination. These included local (pain, redness, 
swelling and induration) and general events such as fever, headache, malaise, chills, nausea, 
vomiting, myalgia and arthralgia. Blood samples for laboratory testing were collected at 
screening, 2-4 and 8 weeks after the final immunization. The laboratory tests included 
complete blood count, alanine aminotransferase, total and direct bilirubin, random blood 
glucose and creatinine. Urinalysis, pregnancy and HIV tests were performed at screening, on 
the day of immunization and on the final visit. Twelve lead electrocardiographs and troponin 
testing were performed before HIV-MVA vaccination and two weeks post vaccination to 
monitor for peri-myocarditis. 
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4.4 Immunogenicity assessment 
4.4.1  Humoral immunogenicity assessment  
HIV-specific binding antibodies (Study 1, II and IV) 
Testing of binding antibodies to recombinant HIV-1 CM243 CRF01_AE gp120 (Protein 
Science Corp), recombinant HIV-1 96ZM651 subtype C gp140 protein (provided by the 
Centre for AIDS Reagents, NIBSC Potter Bar, UK), HIV-1 IIIB subtype B gp160 (Advanced 
Biotechnologies, Inc., Columbia, MD) or recombinant CN54gp140 subtype C was performed 
using an ELISA. Data were reported as reciprocal endpoint titers.  
Binding antibodies to scaffolded HIV-1 envelope V1V2 (Study III) 
IgG binding antibodies to scaffolded gp70 V1V2 protein was performed by ELISA, as 
described in paper III. The testing included recombinant gp70 (MLV)-V1V2 protein 
(CRF01_AE A244, subtype C CN54 or subtype B Case A, Immune Technology Corp., New 
York, USA). Data were expressed as end-point titers, which were calculated as the reciprocal 
of the highest dilution that yielded an absorbance value above two times the mean of the pre-
immunization value.  
Assessment of V1V2 specific IgG subclasses (Paper III) 
Testing for IgG specific subclasses of antibodies to gp70 V1V2 CRF01_AE A244 and gp70 
V1V2 Consensus C was performed using ELISA. Results are expressed as end-point titers as 
described in paper III.  
Surface Plasmon resonance (SPR)/Biacore assay (Study III) 
Measurements of antibodies to Cyclic V2 of HIV-1 Env were performed with a Biacore T100 
as described in paper III.  
Infectious molecular clone (IMC)/PBMC NAb assay (Study I and IV) 
Neutralizing activities were measured using a PBMC assay, employing infectious molecular 
clones (IMC) carrying the luciferase gene from Renilla reniformis (LucR) as a reporter. The 
IMCs used were: CM235 CRF01_AE, SF162 subtype B, BaL subtype B and GS015 subtype 
C. The method is detailed in study I and IV. The percent neutralization of the post-
vaccination serum was calculated based on the level of virus growth in the presence of the 
same dilution of pre-vaccination serum and neutralization values greater than 50% were 
considered positive.  
A standard PBMC-based NAb assay using a p24 read out (Study II) 
NAb was measured against SF162 subtype B and CM244 CRF01_AE in a standard PBMC-
based NAb assay using a p24 read out as described in study II. Neutralization titers were 
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defined as the reciprocal of the highest serum dilution, giving at least a 90% reduction of 
HIV-1 p24-antigen compared to virus control. 
TZM-bl pseudovirus NAb assay (Study I, II and IV) 
NAb activities were measured using pseudoviruses and a luciferase-based assay in TZM-bl 
cells against CM235 CRF01_AE, SF162 subtype B, and GS015 subtype C (study I &IV) and 
SF162 and subtype C 93MW965.26 pseudotyped viruses (study II). The assay measures the 
reduction in luciferase reporter gene expression in TZM-bl cells with a single round of 
pseudovirus infection. The inhibition percentage was calculated as compared to relative 
luminescence units (RLU) in the virus control wells, after subtraction of background (cells 
alone) RLU. A result ≥ 50% is considered to be a positive response. 
IgG depletion from serum (Study I) 
IgG depletion was performed on whole vaccinees sera using protein G Sepharose beads (GE 
Health care Bio-Science Corp, USA) according to the manufacturer’s instructions.  
NK cell depletion from PBMC (Study I) 
NK cell depletion was performed on cryopreserved PBMC using mouse anti-human CD16 
and CD56 antibodies (Invitrogen, Carlsbad CA) and Dynabeads (M-280) coated with sheep 
anti-mouse IgG (Invitrogen, Carlsbad CA), as per the manufacturer’s instructions. The 
neutralizing activities were then evaluated using NK cell-depleted PBMC versus bulk PBMC.  
Infection of CEM.NKRCCR5 cell line with HIV-1 IMC (Study I, II and IV)  
For ADCC assays, IMCs were titrated in order to achieve maximum expression within 36–48 
hours after infection, as described in study I. Assays performed using the infected target cells 
were considered reliable if the percentage of viable p24+ target cells was ≥ 20% on the day of 
testing. 
ADCC-GranToxiLux (ADCC-GTL) assay (Study I and II) 
ADCC-mediating antibodies were measured by a flow cytometry GTL-based assay using 
gp120 coated target cells as described in study I. The CEM.NKRCCR5 target cells were 
coated with recombinant gp120 HIV-1 protein derived from Env of HIV-1 CM243 
CRF01_AE (GenBank accession no. AY214109; Protein Sciences Corporation) or HIV-1 
gp120 SF162 subtype B (GenBank accession no. AAT67508; Immune Technology Corp). 
PBMCs were obtained from an HIV- seronegative healthy donor. The results were expressed 
as a percentage of Granzyme B (GzB) activity positive cells. The final results were expressed 
after subtracting the background from the percentage of GzB activity observed under the 
conditions containing effector and target cell populations in the presence of vaccinee serum. 
The ADCC-mediating antibody titer was defined as the reciprocal of the highest dilution 
indicating a positive GzB response (>8% GzB activity) after background subtraction as 
described by Pollara et al [189]. 
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ADCC-luciferase assay (Study I, II and IV) 
In this assay, measurement of ADCC-mediating antibodies was performed using 
Env.IMC.LucR virus-infected targets cells as described in study I. The Env-IMC-LucR 
viruses used were subtype CRF01_AE HIV-CM235- 2-LucR.T2A.ecto/293T (CM235 IMC) 
(GenBank accession number AF259954.1) and SF162.LucR.T2A.ecto/293T (SF162 IMC) 
(GenBank accession number EU123924), respectively. ADCC activity was measured as the 
percent of loss of luciferase activity observed in the presence of serum. The ADCC-mediating 
antibody titer was defined as the reciprocal of the highest dilution indicating a positive 
specific killing (>15% specific killing activity determined based on the responses observed 
before immunization to allow for 2% false positive rate), after background subtraction. 
4.4.2 Cellular immunogenicity assessment  
IFN-γ ELISpot assay (Study II and IV) 
IFN-γ ELISpot was performed on freshly isolated PBMCs using the h-IFN-gamma ELISpot 
PLUS kit in a two-step detection system (Mabtech, Nacka, Sweden). Results were expressed 
as spot forming cells (SFC) per million PBMC. ELISpot responses were considered positive 
if the number of spot-forming cells was >4 times the background and baseline value and >55 
SFC/106 PBMCs. Data were excluded from analyses if the background responses in medium 
wells exceeded 60 per million PBMCs. 
Lymphoproliferation assay (Study IV) 
Tritiated [3H]-thymidine lymphoproliferation assay (LPA) was performed as described in 
study IV. T cell proliferation was reported as a stimulation index (SI), determined by dividing 
the mean counts per minute of the antigen-stimulated wells by the mean of the unstimulated 
control wells. A SI >6 was considered positive, based on the mean reactivity of 57 healthy 
Tanzanian volunteers. 
4.5  Data analysis  
The safety analysis dataset included all solicited, non-solicited and routine laboratory data 
that were collected after the first vaccination, up to four to eight weeks after the last 
vaccination (HIV-MVA or CN54rgp140/ GLA-AF). The solicited and non-solicited events 
were summarized according to the maximum grade of severity reported. Laboratory events 
were included if they were new or had increased in grade and summarized by grade.  
The analysis of immunological data was performed using GraphPad PRISM version 6 
(GraphPad Software, Inc., La Jolla, CA, USA). The Wilcoxon rank test was used to 
determine statistical significance between bulk and NK cell depleted PBMCs. The Mann-
Whitney test was used to compare the magnitudes of ADCC responses, neutralizing titers, 
binding antibody titers and IFN-γ ELISpot responses between the vaccination groups (Study I 
& IV). For pairwise analysis, the Wilcoxon matched-pair signed rank test was used to 
 26 
compare the magnitudes of humoral and cellular immune responses before and after the 
vaccinations (Study II & III). Fischer’s exact test was used for comparisons of frequencies. 
Correlations were determined by the Spearman rank correlation method used for non-
parametric data. A two-sided p-value of 0.05 was considered statistically significant. 
4.6 Ethical consideration  
The HIVIS03, HIVIS06 and TaMoVac/rgp140 trial protocols were approved by Tanzania’s 
National Health Research Ethics Committee, the Senate Research and Publications 
Committee of the Muhimbili University of Health and Allied Sciences (MUHAS), and the 
Mbeya Medical Research Ethics Committee. The Regional Ethics Committee, Stockholm, 
Sweden, also approved the studies. The Tanzania Food and Drugs Authority approved the use 
of the vaccine candidate products for humans in Tanzania. All trials were conducted in 
accordance with the International Council of Harmonization and Good Clinical Practice 
guidelines. Written informed consent was obtained from all volunteers before enrollment.  
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5 RESULTS AND DISCUSSION  
5.1 Functional antibody responses in healthy individuals primed with 
three HIV-DNA and boosted with two HIV-MVA immunizations 
(Paper I)  
We previously conducted a phase I/II HIV vaccine trial (HIVIS03) among healthy adult 
volunteers in Dar es Salaam, Tanzania, which included priming three times with HIV-DNA 
followed by boosting twice with HIV-MVA [102]. The majority, 97%, of the vaccinees, 
exhibited IFN-γ ELISpot responses, 93% to Gag and 79% to Env two to four weeks after the 
second HIV-MVA boost. All (100%) vaccinees had HIV-specific lymphoproliferative 
responses. Furthermore, 90% had binding antibodies against subtype B gp160 after the 
second HIV-MVA. There were no NAb demonstrated in the TZM-bl pseudovirus 
neutralization assay. However, using an IMC/PBMC assay, high NAb response rates were 
demonstrated, 83% against CM235 CRF01_AE, 72% against SF162 subtype B and 31% 
against BaL subtype B.  
In paper I, we evaluated the functional antibody responses (NAbs and ADCC-mediating 
antibodies) in HIVIS03 vaccinees’ sera collected at baseline and four weeks after the second 
HIV-MVA vaccination. We measured the magnitude of NAbs against the CM235 
CRF01_AE. High NAb titers were detected after the second HIV-MVA vaccination (median 
357, range 20-2868) using the IMC/PBMC assay, while no NAbs were demonstrated using 
the pseudovirus/TZM-bl assay. HIV NAbs detected in the IMC/PBMC assay against the 
CM235 IMC were IgG-mediated. Discrepancies in the NAb results using the two assay 
platforms have been reported previously [190]. In addition, in a study by Choudhry et al 
using a monoclonal antibody, cross-clade neutralization was demonstrated in a PBMC assay, 
but no neutralization in a TZM-bl pseudovirus assay [191]. The possible explanation for the 
discrepancy is that the TZM-bl pseudovirus assay is a single round assay and mainly 
measures the inhibition of virus binding and entry compared to an IMC/PBMC assay, which 
encompasses multiple rounds of infection, thus catching all the potential inhibition stages of 
the virus replication. 
The interaction between antibodies and NK cells has been shown to enhance neutralization of 
HIV-1 [192,193]. We assessed the potential role of NK cells in the PBMC NAb assay 
activity. Sera from nine HIVIS03 vaccinees with NAb titer above 200 were tested against the 
CM235 CRF01_AE and BaL subtype B IMC using bulk and NK cell-depleted PBMC in the 
neutralization assay four weeks after the second HIV-MVA boost. The neutralizing activity 
was significantly removed (but not completely) when using NK cell-depleted PBMC 
compared to bulk cells (p = 0.0039), (figure 2 in paper 1) suggesting a role for Fc-receptor-
mediated antibody function. A similar result was also demonstrated when tested against BaL 
subtype B IMC. The remaining small neutralizing activity detected following NK-cell 
depletion from PBMC may be attributed to other Fc-receptor-bearing cells in the bulk PBMC, 
such as monocytes and/or macrophages.  
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Following the demonstration of the role of NK cells in the neutralizing activity of the 
vaccinees sera we tested whether ADCC-mediating antibodies were induced by the HIVIS03 
vaccine regimen. ADCC activity was measured in sera from 29 vaccinees collected at 
baseline, two months after the first HIV-MVA and four weeks after the second HIV-MVA 
boost using both gp120-coated target cells (ADCC-GTL assay) and IMC-infected target cells 
(ADCC-Luciferase assay), against the vaccine subtype homologous CRF01_AE (Env E) and 
subtype B viruses. The results are summarized in Table 3.  
Table 3. Frequency of antibody response four weeks after the second HIV-MVA 
(HIVIS03 trial)  
Assay and antigen Subtypes Positive /total number  
tested (%) 
Reference 
ELISA binding antibody      Paper 1  
gp120 CM243  AE 29/29 (100)  
gp140 96ZM651  C 29/29 (100)   
gp160 IIIB B 26/29 (90)  Bakari et al [102] 
ADCC-GTL     Paper 1  
gp120 CM243  AE 24/28 (86)   
gp120 SF 162  B 21/28 (75)   
ADCC-luciferase      Paper 1  
IMCCM235  AE 28/29 (97)   
IMCSF162  B 19/28 (68)   
PBMC neutralization assay     Bakari et al [102] 
IMC CM235 AE 24/29 (83)   
IMC SF 162 B 21/29 (72)   
IMC BaL B   9/29 (31)   
TZM-bl pseudovirus assay     Bakari et al [102] 
Paper I &II 
 CM 235, SF 162, Bal MW965.26 AE, B, B & C 0/29   
gp70V1V2 ELISA      Paper III 
IgG gp70V1V2 A244  AE  28/29 (97)    
IgG gp70V1V2 CN54  C 14/29 (48)   
IgG gp70V1V2 Case A2  B  3/29 (10)    
IgG1 gp70V1V2 A244  AE 20/30 (67)   
IgG3 gp70V1V2 A244  AE 4/30 (13)   
IgG1 &IgG3 gp70V1V2  
Consensus C 
C 0/30   
ADCC-GTL, antibody-dependent cellular cytotoxicity-GranToxiLux assay; IMC, infectious molecular clone; 
ELISA, enzyme-linked immunosorbent assay; PBMC, peripheral blood mononuclear cell. 
 
No ADCC activity was detected at baseline and two months after the first HIV-MVA boost in 
either of the two ADCC assays. After the second HIV-MVA vaccination, the frequency and 
magnitudes of ADCC-mediating antibody responses were higher to CRF01_AE (86%, 
median titer 1841 in the ADCC-GTL assay and 97%, median titer 1076 in the ADCC-
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Luciferase assay), compared to subtype B (75%, median titer 876 in the ADCC-GTL assay 
and 68%, median titer 715 in the ADCC-Luciferase assay) (Table 3).  
The magnitude of ADCC-mediating antibody responses correlated well with the NAb titer 
against IMC CM235 (Figure 5a in paper 1). Higher titers of HIV-1 gp120 specific ADCC-
mediating antibodies have been reported to correlate inversely with the rate of HIV disease 
progression, whereas significantly lower titers of ADCC antibodies were detected among 
HIV-1 infected rapid progressors compared to non rapid-progressors [151]. Moreover, studies 
conducted in non-human primates have shown that ADCC antibodies correlated with reduced 
acute viremia, following a mucosal challenge with pathogenic SIV in the vaccinated rhesus 
macaques [108,109] In the RV144 trial, ADCC-mediating antibodies were reported to 
correlate inversely with reduced risk of HIV infection in vaccinees with low titers of IgA Env 
binding antibody [171].  
We also assessed the binding antibody responses by ELISA at baseline and four weeks after 
the second HIV-MVA (Table 3). All 29 (100%) vaccinees had detectable antibodies both to 
CRF01_AE gp120 (median titer 3200) and to HIV-1 subtype C gp140 (median titer 3200) 
after the second HIV-MVA vaccination. The binding antibody titers for these two subtypes 
were significantly higher than the previously reported titers against subtype B gp160, tested 
in the same vaccinees (Figure 6a in paper 1) [102]. A positive correlation was demonstrated 
between NAb titers against the CM235 IMC and the binding antibody titers to subtype C 
gp140. Furthermore, ADCC antibody titers against CM243 gp120 coated target cells 
correlated well with CM243 gp120 binding antibodies (Figure 6b & 6c in paper 1). A 
correlation between ADCC activity and anti-gp140 response has been demonstrated in SIV-
infected rhesus macaques [155]. 
Overall, the three HIV-DNA priming and two HIV-MVA boosting immunizations generated 
potent functional antibody responses in a high proportion of healthy Tanzanian individuals. 
NK cells were responsible for the majority of the neutralizing activity observed in the 
IMC/PBMC neutralizing assay, supporting the observation of potent ADCC-mediating 
antibody responses. 
5.2 Durability of immune responses after three HIV-DNA and two HIV-
MVA immunizations and the effect of a late third HIV-MVA 
immunization (Paper II and III) 
In studies in paper II and III, we investigated the duration of immune responses in individuals 
primed with HIV-DNA and boosted with HIV-MVA in the HIVIS03 trial and the effect of an 
additional late third HIV-MVA immunization. Twenty volunteers who previously received 
three HIV-DNA and two HIV-MVA vaccinations were given a third HIV-MVA 
immunization three years after the second HIV-MVA boost, the HIVIS06 trial. The late third 
HIV-MVA vaccination was safe and well tolerated. 
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Binding Env antibody responses were measured in the 20 vaccinees who received a third 
HIV-MVA boost. Sera were tested at baseline, four weeks after the second HIV-MVA boost, 
at the time of the third HIV-MVA, three years after the second HIV-MVA and four weeks 
after the third HIV-MVA vaccination. The results are summarized in Table 4.  
Table 4. Frequency of immune responses before and after the third HIV-MVA 
vaccination (HIVIS06 trial) 
Assay and antigen Subtypes After 2nd 
HIV-MVA 
At the time of the 
3rd HIV-MVA 
After 3rd 
HIV-MVA 
  Pos/total no. 
tested (%) 
Pos/total no. 
tested (%) 
Pos/total no. 
tested (%) 
ELISA binding antibody     
gp120 CM243 AE 20/20 (100) a 18/20 (90) 20/20 (100) a 
gp140 96ZM651 C 20/20 (100) a 18/20 (90) 20/20 (100) a 
gp160 IIIB B 17/19 (89) a 17/20 (85) 17/20 (85) a 
Neutralization     
PBMC assay with p24 read 
out (SF162, CM244) 
B, AE 0/20 a ND 0/20 a 
TZM-bl assay 
(SF162, MW965.26) 
B 0/20 a ND 0/20 a 
ADCC-GTL     
gp120 CM243 AE 16/18 (88) a 16/19 (84) 18/19 (95) a 
gp120 SF 162 B    
ADCC-luciferase     
IMC CM235 AE 18/19 (95) a 14/20 (70) 14/20 (70) a 
IMC SF162 B 13/18 (72) a 9/19 (47) 14/19 (74) a 
gp70V1V2 ELISA     
IgG gp70V1V2 A244 AE 19/19/ (100) a 15/20 (75) 19/20 (95) a 
IgG gp70V1V2 CN54 C 9/19 (47) a 2/20 (10) 4/20 (20) a 
IgG gp70V1V2 Case A2 B 3/19 (16) a 0/20 2/20 (10) a 
IgG1 gp70V1V2 A244 AE 17/20 (85) a 5/20 (25) 13/20 (65) a 
IgG3 gp70V1V2 A244 AE 3/20 (15) a 0/20 1/20 (5) a 
IgG1 &IgG3 Consensus C C 0/20 a 0/20 0/20 a 
ELISpot     
Gag SMI A ND 13/19 (68) 17/20 (85) b 
Gag CMDR A 16/18 (89) b 12/19 (63) 18/20 (90) b 
Env CMDR E 16/18 (89) b 8/19 (42) 18/20 (90) b 
Gag or Env  16/18 (89) b 14/19 (74) 19/20 (95) b 
Anti-vaccinia neutralization    
Strain Elstree  19/20 (95) a 20/20 (100) 20/20 (100) a 
ADCC-GTL, antibody-dependent cellular cytotoxicity-GranToxiLux assay; IMC, infectious molecular clone; 
ELISA, enzyme-linked immunosorbent assay; ND, Not done; PBMC, peripheral blood mononuclear cell; Pos, 
Positive; no, Number. aTesting performed 4 weeks after the HIV-MVA vaccination. bTesting performed 2 weeks 
after the HIV-MVA vaccination  
A high proportion of the vaccinees showed durable binding antibody responses, 90% to 
subtype C gp140 and 85% to subtype B gp160, three years after the second HIV-MVA. In a 
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study by Goepfert et al, where volunteers were immunized twice with JS7 DNA and twice 
with MVA/HIV62B vaccines, binding antibodies to gp140 were elicited in 100% of the 
vaccinees two weeks after the final immunization. However, the responses decreased by 
15.6% 24 weeks later [194], indicating a shorter durability of antibody responses compared to 
our study where the response declined by 5-10% three years after the second HIV-MVA 
immunization. In the same study by Goepfert et al, there was no decrease in the response rate 
of gp140 antibodies 24 weeks after three MVA/HIV62B vaccinations [194]. Following the 
third HIV-MVA vaccination in our study, the antibody response rate to subtype C gp140 
increased to 100%. We also observed a significant increase in the magnitude of antibodies 
both to subtype C gp140 and subtype gp160 B after the third HIV-MVA (Figure 2 in paper 
II), showing that the antibody titer can be maintained by further HIV-MVA boosting. There 
was also a positive correlation of antibody titers against subtype C gp140 and subtype gp160 
B. 
ADCC-mediating antibody responses were measured using both gp120-coated target cells 
and IMC–infected target cells at three time points (Table 4). ADCC responses to subtype E 
CM243 gp120–coated cells were detected in 88% and to CM235 CRF01_AE–infected cells 
in 95% of evaluable vaccinees after the second HIV- MVA. The majority of the vaccinees 
still had ADCC-mediating antibodies three years after the second HIV-MVA vaccination, 
84% against CRF01_AE gp120-coated cells (median titer 499) and 70% against CRF01_AE-
infected cells (median titer 239) indicating extraordinary durability. Following the third HIV-
MVA vaccination the ADCC response to CRF01_AE gp120–coated cells increased to 95% 
(median titer 683). Although the ADCC response rate against CM235 CRF01_AE–infected 
cells remained the same after the third HIV-MVA, the magnitude increased significantly 
from a median titer of 239 to 578, p=0.004. After the second HIV-MVA, 72% of the 
vaccinees had ADCC response to SF162 subtype B–infected cells and 47% before the third 
HIV-MVA three years later, which increased to 74% after the third HIV-MVA boost. The 
magnitude increased significantly from a median titer of 204 to 681 (p = 0.0002) nearly to the 
same level (median 571, p = 0.82) as after the second HIV-MVA (Figure 3 in paper II). These 
findings demonstrate that priming with three HIV-DNA and boosting with two or more HIV-
MVA, elicited durable and high titers of ADCC-mediating antibody responses in a significant 
proportion of vaccinees and that a late third HIV-MVA significantly boosted the ADCC 
responses. A lower frequency of ADCC activity was detected using 51Cr labeled CEM.Nkr 
coated cells, 40% against CM243 CRF01_AE gp120 and 30% to MN subtype B gp120 in the 
RV158 trial among vaccinees who received three MVA-CMDR immunizations without HIV-
DNA priming [195]. 
Several methods have been employed for the assessment of NAbs in HIV vaccine trials using 
different types of target cells, culture conditions or signals to quantify the viral neutralization 
[190,193]. In the HIVIS06 study, NAb was measured using a PBMC assay with a p24-read 
out, as well as the TZM-bl based neutralizing assay. No NAb was detected in any of the two 
assays using sera collected from the vaccinees before and after the third HIV-MVA (Table 4). 
This finding is contrary to our previous report where a high frequency of NAb responses, up 
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to 83%, was demonstrated against CM235 CRF01_AE using an IMC/PBMC assay [102]. 
The type of the PBMC neutralization assay used could explain the difference in neutralizing 
activity demonstrated. In the HIVIS06 study, we used a standard PBMC assay with a HIV 
p24 antigen read out, whereas the IMC/PBMC assay was used in the HIVIS03 study. In the 
IMC/PBMC assay the antibodies stay with the cells and virus for the entire four days duration 
of the assay, allowing other effector cells present in the PBMC cells, such as natural killer 
cells or monocytes, to affect the potential functional role, in contrast to the PBMC assay with 
a HIV p24 read out, where serum and virus are washed out after 24 hrs of incubation.  
Antibodies to V1V2 of HIV Env were reported to correlate with reduced risk of HIV 
infection in the RV144 trial, the only trial that has shown an efficacy of 31.2 % [171]. In 
paper III, we analysed the VIV2-specific antibodies in plasma samples collected from 29 
HIVIS03 vaccinees and 12 placebo recipients at baseline (V3) and four weeks after the 
second HIV-MVA (V21) and in 20 HIVIS06 vaccinees at the time of the third HIV-MVA, 
three years after the second HIV-MVA (V62) and four weeks after the third HIV-MVA 
(V64). Of the 29 vaccinees assessed, 28 (97%) had IgG binding antibodies to V1V2 of 
CRF01_AE A244, 14 (48%) to subtype C CN54 and three (10%) to subtype B Case A2, four 
weeks after the second HIV-MVA vaccination (Table 3).  
Of the 20 vaccinees who received an additional late third HIV-MVA immunization, all 19 
(100%) evaluable vaccines exhibited V1V2 IgG antibodies to subtype E after the second 
HIV-MVA. The V1V2 antibody response showed an excellent durability. Three years after 
the second HIV-MVA, 75% of the vaccinees still had V1V2 antibody responses. In contrast, 
in the longitudinal follow-up study in the RV144 trial, Yates et al reported a high V1V2 IgG 
response rate of 97% to gp70 B Case A2 V1V2 at week 26 (2 weeks after the last 
immunization), which declined to 0% at week 156 (33 months after the last immunization).  
Similarly, the V1V2 IgG response against subtype C.1086 V1V2 tags was 97% and 
decreased to 8% at week 156 [173].  
Following the third HIV-MVA immunization in our study, the V1V2 IgG response rate to 
CRF01_AE A244 increased to 95%. The magnitude of V1V2-specific antibody against 
CRF01_AE A244 increased significantly from a median titer of 400 at the three-year time 
point to a median of 1600, p<0.0001 after the third HIV-MVA, but not to the same level as 
after the second HIV-MVA (median titer 3200, p=0.0257) (Figure 1 in paper III). The 
response rate to V1V2 of subtype C CN54 declined from 47% four weeks after the second 
HIV-MVA to 10% three years later, but increased to 20% four weeks after the third HIV-
MVA boost (Table 4). Antibody responses to V1V2 subtype B Case A2 were rare. None of 
the placebo recipients had antibodies to the three scaffolded gp70 V1V2 proteins.  
Given that V1V2 IgG antibodies were detected in the majority of the vaccinees, we next 
tested V1V2 IgG subclass (IgG1 and IgG3) responses to subtype E A244 and subtype C 
Consensus C (Table 4). A high proportion of vaccinees (85%) had anti-V1V2 IgG1, four 
weeks after the second HIV-MVA, with three years durability in 25%. The response rate was 
boosted to 65% four weeks after the third HIV-MVA, a response rate similar to that seen after 
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the second HIV-MVA, p=0.273. The V1V2-specific IgG3 response rate was 15% after the 
second HIV-MVA and 5% after the third HIV-MVA. Likewise, the magnitude of anti-V1V2 
IgG1 to subtype E A244 was also boosted significantly, from a median titer of 100 at the time 
of the third HIV-MVA to 200, four weeks after the third HIV-MVA, p= 0.001 (Figure 2 in 
paper III). In this study we observed higher responses of V1V2 IgG1 than V1V2 IgG3 and 
this reflects the overall level of IgG1 and IgG3 in the plasma. Similarly, V1V2 IgG1 
responses were more frequently detected than V1V2 IgG3 responses in the RV144 trial [164]. 
Notably the IgG1 and IgG3 antibodies targeting the crown of the HIV Env V2 loop were 
more frequently elicited in the RV144 Thai trial than in the non-protective VAX003 trial 
[164]. The frequency and magnitude of V1V2 IgG3 responses were correlated with a 
decreased risk of HIV-1 infection in the RV144 trial [173]. In addition the rate of V1V2 IgG3 
responses was higher in the RV144 trial than in the VAX003 trial [173]. Furthermore, 
vaccine–induced V1V2 IgG3 and IgG responses were not predictive of one another [173].  
Antibodies to cylic V2 peptides were also measured against subtype E A244 and consensus C 
using SPR/Biacore analysis at four time points (Figure 3 in paper III). The level of reactivity 
decreased significantly three years after the second HIV-MVA (p<0.0001), and could be 
boosted by the third HIV-MVA immunization (p<0.0001). None of the vaccinees had 
antibody reactivity to MN subtype B. No antibody reactivity was detected among placebo 
recipients. The Biacore data reported here are consistent with the ELISA findings.  
This study of V1V2 antibodies had some limitations. V1V2 IgG2 and V1V2 IgG4 antibodies 
were not evaluated. It has been speculated that higher levels of V1V2 IgG2 and IgG4 
antibodies may have interfered with the ADCC function leading to lack of protection in the 
VAX003 trial in contrast to the RV144 trial that demonstrated an efficacy of 31.2%. 
Furthermore, the lack of protection in the VAX003 trial has been reported to be associated 
with repeated immunizations of higher doses of vaccine antigen without adequate adjuvant 
signals [164], causing the IgG subclass switching.  
In the HIVIS03/06 vaccinees, no correlation was demonstrated between the V1V2 specific 
antibodies and ADCC-mediating antibodies before and after the third HIV-MVA vaccination, 
suggesting that these antibodies target different epitopes (Table 4 in paper III). IgG antibodies 
specific to V1V2 have been reported to inhibit the viral entry, possibly by blocking the 
binding of V1V2 to the co-receptor CCR5 or to the integrin α4β7 receptor [196-198]. 
Durable cellular immune responses were also demonstrated in the HIVIS06 trial. A high 
proportion of vaccinees still had detectable IFN-γ ELISpot responses three years after the 
second HIV-MVA vaccination, 63% to Gag-CMDR and 42% to Env-CMDR. Following the 
third HIV-MVA, the IFN-γ ELISpot response increased to 95%, 90% to both Gag and Env-
CMDR. The magnitude of responses to both Gag and Env declined significantly three years 
after the second HIV-MVA and was boosted significantly after the third HIV-MVA, to a 
level slightly lower than the level detected after the second HIV-MVA (Figures 4a & 4b in 
paper II). In a study where volunteers were given three doses of MVA-CMDR vaccination 
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without DNA priming, lower IFN-γ ELISpot responses were reported, 30% to Gag and 60% 
to Env [195].  
HIV-DNA priming in the HIVIS03 trial was administered either by the id or im route, using a 
needle free Biojector® device. After the second HIV-MVA, no significant difference in NAb 
was detected between HIV-DNA id-primed and im-primed vaccinees (p = 0.67). Similarly, 
the ADCC-mediating antibody responses did not differ significantly between HIV-DNA id or 
im primed vaccinees at all testing time points, using both gp120 coated cells and IMC-
infected target cells for the virus included. Interestingly, in the HIVIS06 study, we noted that 
the magnitude of the IFN-γ ELISpot Env responses among the previously HIV-DNA id 
primed vaccinees was significantly higher at the three year time point and after the third HIV-
MVA boost, than in the HIV-DNA im recipients, suggesting that id priming may be better 
than im priming for maintaining durable Env responses (Figure 4d in paper II). 
The effect of vaccinia NAbs was also assessed before and after the HIV-MVA immunizations 
(Figure 5 in paper II). One volunteer had detectable vaccinia NAbs pre-vaccination. All 
vaccinees (100%) developed vaccinia-NAbs after HIV-MVA immunizations detectable at all 
the three-time points. In our study the presence of vaccinia NAbs did not affect the induction 
of humoral or cellular immune responses following a late third HIV-MVA. The finding 
reported here is consistent with our previous report, where the same vaccine regime was used 
[199]. Collectively, these findings suggest that a vaccinia vector-based vaccine can be used 
even in vaccinia pre-exposed individuals. 
In summary, the HIV-DNA/MVA prime-boost regimen elicited potent humoral and cellular 
immune responses with extraordinary durability that persisted for more than three years. 
Furthermore, the third HIV-MVA vaccination significantly boosted the antibody and cellular 
immune responses.  
5.3 Safety and immunogenicity of boosting with CN54rgp140/GLA-AF 
following HIV-DNA/MVA immunizations (Paper IV) 
This study was performed as an amendment to a phase IIa randomized placebo-controlled 
trial, in which healthy Tanzanian volunteers received three HIV-DNA immunizations or 
placebo followed by two HIV-MVA vaccinations or placebo (TaMoVac 01). Forty 
volunteers (35 vaccinees and 5 placebo recipients) were recruited to receive two 
CN54rgp140/GLA-AF immunizations, 31 to 70 weeks after the second HIV-MVA. The 
protein boost was safe and well tolerated, except in one volunteer with mild pre-existing 
hypoglycemia who developed severe hypoglycemia, an event that has not been reported in 
previous trials using the same protein vaccine.  
Env-specific binding antibody responses were significantly boosted by the 
CN54rgp140/GLA-AF immunizations. Env protein that matched the CN54rgp140/GLA-AF 
immunogen was included in the analyses of binding antibodies. The binding IgG responses 
were analyzed against subtype C, B and CRF01_AE Env four weeks after the second HIV-
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MVA and four weeks after the first and second CN54rgp140/GLA-AF immunizations. 
Overall the response rate and titers were higher against subtype C CN54 rgp140 than against 
subtype B gp160 and CRF01_AE gp120. After the second HIV-MVA vaccination, 97% of 
the vaccinees exhibited binding antibodies to subtype C CN54 rgp140. The frequency 
increased to 100% after the first and second CN54rgp140/GLA-AF vaccination. The 
magnitude increased significantly both after the first (median titer 8100) and second (median 
titer 24300) CN54rgp140/GLA-AF immunization compared to after the second HIV-MVA 
immunization (median titer 900) p<0.0001 (Figure 2 in paper IV). In the Thai RV144 trial in 
which individuals were primed with four ALVAC-HIV vCP1521 and boosted with two 
AIDSVAX B/E immunizations, delivered at the time of the two last ALVAC immunizations, 
high Env antibody response rates were demonstrated at 12 months, 98% to both CRF01_AE 
gp120 A244 and subtype Bgp120 MN with geometric mean antibody titers (GMT) of 14558 
and 31207, respectively [119]. In TaMoVac 01, the frequency of binding antibodies to 
subtype B gp160 was 87% after the second HIV-MVA vaccination. The response rate was 
further boosted by subtype C CN54rgp140/GLA-AF vaccination to 100% after the first and 
to 97% following the second protein boost. The median titer to subtype B gp160 increased 
from 400 after the second HIV-MVA, to 2700 after the two CN54rgp140/GLA-AF boost 
vaccinations. In addition, the antibody response rate to CRF01_AE gp120 was 80% after the 
second CN54rgp140/GLA-AF boost, a significant increase, as compared to after the second 
HIV-MVA (49%), p=0.012.  
ADCC-mediating antibodies were measured using target cells infected with Env-IMC-LucR 
viruses, including CM235 CRF01_AE, subtype B SF 162 and subtype C 1086. After the 
second HIV-MVA, 10/35 (29%) of the vaccinees demonstrated ADCC-mediating antibody 
responses to CM235 CRF01_AE and 9/35 (25%) after the second CN54rgp140/GLA-AF 
immunization. The magnitude of the ADCC-mediating antibody responses against CM235 
CRF01_AE did not differ significantly after the second HIV-MVA (median titer 1801, range 
201–4772) and after the second CN54rgp140/GLA-AF immunization (median titer 491, 
range 249–18140) p = 0.802 (Figure 3 in paper IV). Only one of 35 vaccinees had ADCC-
mediating antibodies to SF 162 subtype B and HIV 1086.c subtype C IMC after the second 
CN54rgp140/GLA-AF immunization (Table 5).  
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Table 5: Comparison of immune responses elicited following immunization with two 
HIV-MVA, three HIV-MVA and two Env protein boosts in individuals primed with 
three HIV-DNA vaccinations. 
 
     HIVIS03/06 trial TaMoVac01/rg140 trial 
Assay and Antigen Subtypes After two 
HIV-MVA 
n=29 
After three 
HIV-MVA 
n=20 
After two 
HIV-MVA 
n=35 
After two Env 
Protein 
n=35 
   Pos/total no. 
tested (%) 
Pos/total no. 
 tested (%) 
Pos/total no. 
 tested (%) 
Pos/total  
  no. tested (%) 
      
ELISA binding Ab      
gp120 CM243  AE 29/29 (100) 20/20 (100)   
gp120 93TH975 AE   17/35 (49) 28/35 (69) 
gp140 96ZM651  C 29/29 (100) 20/20 (100) 34/35 (97) 35/35 (100) 
gp160 IIIB B 26/29 (90) 17/20 (85) 25/30 (87) 28/29 (97) 
ADCC-GTL      
gp120 CM243  AE 24/28 (86)    
gp120 SF 162  B 21/28 (75)    
ADCC-luciferase      
IMC CM235 AE 28/29 (97) 14/20 (70) 10/35 (29) 9/35 (28) 
IMC SF162  B 19/28 (68) 14/19 (74) 2/35 (6) 1/35 (3) 
IMC 1086 C   0/35 1/35 (3) 
IMC/PBMC neutralization 
assay 
    
IMC CM235 AE 24/29 (83)  2/35 (6) 2/35 (6) 
IMC SF 162 B 21/29 (72)  1/35 (3) 0/35 
IMC GS015 C   7/35 (20) 11/35 (31) 
IMC BaL B 9/29 (31)    
PBMC assay with 
p24 read out  
B, AE  0/20   
SF162, CM244      
TZM-bl pseudovirus      
CM235, SF162, 
BaL, MW965.26 
AE, B, B, 
C 
0/29 0/20  0/35 
ELISpot      
Gag CMDR A  23/29 (79) 18/20 (90) 26/33 (79) 17/35 (49) 
Env CMDR E  24/29 (83) 18/20 (90) 26/31 (84) 24/35 (69) 
LPA      
CM235 AE 25/25 (100)   11/14 (79) 
MN B    12/14 (86) 
ADCC-GTL, antibody-dependent cellular cytotoxicity-GranToxiLux assay; IMC, infectious molecular clone; 
ELISA, enzyme-linked immunosorbent assay; ND, Not done; PBMC, peripheral blood mononuclear cell; LPA, 
Lymphoproliferative assay. Pos, Positive; no, Number 
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In general, the functional antibody (ADCC and NAb) response rates in the TaMoVac 01 
study were lower after the second HIV-MVA, as well as after the second CN54rgp140/GLA-
AF vaccinations compared to the response rates reported in the HIVIS03/06 trials where 
volunteers were also primed with three HIV-DNA and boosted with two HIV-MVA 
immunizations (Table 5). The difference may be due to the interval between the HIV-DNA 
prime and HIV-MVA boosts, which was shorter in the TaMoVac 01 trial than in the 
HIVIS03/06 trial. In both trials, the HIV-DNA priming immunizations were given at 0, 1 and 
3 months. However in the HIVIS03 trial, the HIV-MVA boosts were given at 9 and 21 
months i.e. with an interval of 12 months between the first and second HIV-MVA boosts, 
whereas in the TaMoVac 01 trial the HIV-MVA boosts were given at 7.5 and 11.5 months 
i.e. with an interval of only 4 months. Longer intervals between priming and boosting have 
been reported to improve the induction of immune responses [200].  
The impact of combined MVA and adjuvanted Env gp140 protein boost versus sequential 
administration of MVA/gp140 vaccine after DNA priming was recently reported by Joseph et 
al in a phase 1 clinical trial [122]. The overall immunization period was shorter in the 
combined immunization group. No significant impact was observed on the frequency and 
magnitude of Env-specific binding antibody responses to gp140 after combined vaccinations 
compared to sequential immunizations. However, the NAb response observed to the tier 1 
virus was lower and the breadth of T cell responses tended to be lower when the vaccines 
were combined. This study employed a relatively short (4-8 weeks) interval between the 
immunizations and the authors hypothesize that this may have influenced the results [122]. 
We also assessed the IFN-γ ELISpot and LPA responses in TaMoVac 01 vaccinees. The 
frequency and magnitude of IFN-γ ELISpot responses to Env were significantly boosted 
following the second CN54rgp140/GLA-AF immunizations but not the responses to Gag-
CMDR (Figure 4 in paper IV). A lymphocyte proliferation assay (LPA) was performed to 
further evaluate the vaccine-induced T-cell responses in 16 vaccinees from the MUHAS trial 
site. At the time of the first CN54rgp140/GLA-AF immunization, 8/14 (57%) of evaluable 
vaccinees had a proliferative response to subtype B MN, which increased non-significantly to 
12/14 (86%) two weeks after the second CN54rgp140/GLA-AF. The response rate to 
CRF01_AE CM235 was 9/64 (64%) at the time of the first CN54rgp140/GLA-AF, which 
increased to 11/14 (79%) two weeks after the second CN54rgp140/GLA-AF. The magnitude 
of the LPA response to subtype B MN increased significantly after the second rgp140/ GLA-
AF immunization, p = 0.041.  
In conclusion, two immunizations with subtype C gp140 Env protein adjuvanted in GLA-AF 
significantly boosted the Env specific binding antibody responses and Env-specific cellular 
immune responses, but not the functional antibody responses in vaccinees previously primed 
with HIV-DNA and HIV-MVA. 
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6 CONCLUSIONS, RECOMMENDATIONS AND FUTURE 
PLANS 
The HIVIS03 and HIVIS06 studies showed that priming three times with HIV-DNA and 
boosting twice with a recombinant HIV-MVA vaccine induced potent HIV-specific ADCC- 
mediating and Env-binding antibody responses, including V1V2 antibodies, as well as 
cellular immune responses with excellent three-year durability. A late third HIV-MVA 
immunization given three years after the second HIV-MVA was well tolerated and 
significantly boosted both antibody and cellular HIV-specific immune responses, suggesting 
that immune responses could be maintained by regular boosting.  
In study IV (the TaMovac 01 trial), we found a significant enhancement of Env binding 
antibody responses and Env-specific cell-mediated immune responses, after sequential 
boosting with CN54rgp140/GLA-AF protein of volunteers previously primed with three 
HIV-DNA and two HIV-MVA immunizations. However, overall, the immune responses, 
especially functional antibody responses, were not as frequent in the TaMoVac 01 trial 
vaccinees as in the HIVIS03/06 trial vaccinees, which may be due to the shorter interval 
between the HIV-MVA boosts in the TaMoVac 01 trial. This needs further study, and we 
recommend that the time interval between immunizations should be long enough to allow for 
maturation of the immune responses.  
In our studies conducted in Tanzania and those conducted in Sweden using the same HIV- 
DNA vaccine for priming, immune responses were very rarely generated against HIV RT, 
which is expressed by one of the DNA plasmids. The findings suggest that, this plasmid 
could be excluded from the HIV-DNA vaccine.  
Through the HIVI0S03/06 and TaMoVac 01 clinical trials conducted in Tanzania, we have 
gained knowledge towards optimization of the immunization protocol for the HIV-DNA 
prime/ HIV-MVA boost vaccine regimen with and without gp140 protein. Based on the 
immunogenicity results obtained, the potential of the HIV-DNA /MVA prime boost vaccines 
regimen for the induction of potent and durable immune responses has been shown, and we 
therefore recommend this vaccine regimen as a potential avenue in HIV vaccine 
development. Nevertheless, further work is needed. 
Following the HIV vaccine trials reported in this thesis, we were able to conduct a 
multicenter clinical trial involving two sites in Tanzania and one site in Mozambique, the 
phase II TaMoVac 02 trial that investigated the safety and immunogenicity of vaccine 
regimens comparing the use of id HIV-DNA prime alone or with id electroporation, and 
boosting with HIV-MVA alone or in combination with CN54rgp140/GLA-AF protein.  
Preliminary findings showed that intradermal electroporation of HIV-DNA was well tolerated 
but did not potentiate priming by needle-free injection. Simplified HIV-DNA priming by one 
injection in a higher vaccine concentration, induced similar immune responses as compared 
to two injections with lower concentrations. The majority of the vaccinees developed subtype 
  39 
C gp140-binding antibodies. The magnitude of gp140-specific binding antibodies was 
significantly higher after co-administration of rgp140/GLA-AF with HIV-MVA. The 
addition of Env protein to the HIV-MVA boost significantly increased the NAb response to 
homologous subtype C, but not to subtype AE pseudovirus homologous to HIV-MVA.  
The capacity built which includes human resources training, strengthening of laboratory 
infrastructure and establishment of various techniques to evaluate vaccine-induced immune 
responses through the conduct of these trials in Tanzania have paved the way for possible 
future phase IIB and III HIV vaccine efficacy trials. 
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